Publications by authors named "Nikolai Birkbak"
Proc Natl Acad Sci U S A
January 2014
Article Synopsis
- Type 1 diabetes is caused by the destruction of pancreatic β-cells, and researchers are exploring lysine deacetylase inhibitors (KDACi) as potential treatments to protect these cells from inflammation.
- In a study using nonobese diabetic (NOD) mice, the KDACi vorinostat and givinostat were shown to significantly reduce diabetes incidence and improve pancreatic health.
- The treatments increased functional regulatory T-cells while reducing inflammation markers, revealing a specific mechanism involving transcription factor hyperacetylation that could lead to clinical trials for KDACi in treating autoimmune diseases like type 1 diabetes.
